We have a highly distinguished and multidisciplinary Founding Board of Directors composed of leaders within the blood disorders arena.

Andra H. James, MD, MPH

Consulting Professor of Obstetrics & Gynecology, at Duke University Medical Center, and founder of Duke University of Women's Hemostasis and Thrombosis Clinic. An Ob/Gyn and high-risk pregnancy expert, Dr. James is an internationally renowned leader in advancing the optimal treatment and management of women with blood disorders.   

Barbara A. Konkle, MD

Associate Chief Scientific Officer at the Bloodworks North West. Dr. Konkle is also a Professor of Medicine, Division of Hematology, at the University of  Washington. Dr. Konkle has long been committed to improving the care of women with bleeding and clotting disorders through research, clinical care and leadership in national organizations.

Roshni Kulkarni, MD

Professor (emeritus) and Director of Pediatric Hematology/Oncology at Michigan State University. Dr. Kulkarni was the Director of CDC's Division of Blood Disorders and Distinguished Hematology Consultant for CDC. She serves on Boards of national and international organizations, including ASPHO, ATHN, and ISTH, and has received the US FDA Distinguished Service Award.

Janelle L. Davis, JD

Janelle L. Davis, JD, is a partner at Thompson & Knight, LLP, in Dallas, Texas, where her focus areas include healthcare. Ms. Davis has published several articles in leading law journals and related newsletters and has spoken at multiple conferences. She also holds the distinction of being listed in Texas Rising Stars® by Thomson Reuters (Business Litigation; Personal Injury - Products: Defense), for the fourth year in a row, 2013-2016, a distinction received by only 2.5% of Texas's young attorneys.

Anna DeSimone (1950-2012)

Blood Disorders Professional who had long-term experience in both volunteer and staff leadership roles in bleeding disorders, including serving as Director of a non-profit awareness campaign on von Willebrand Disease. Ms. DeSimone held key marketing, public relations and broadcast TV positions.


Leslie J. Graham, MSHA

President and CEO, Primary Care Coalition, Silver Spring, MD. Expertise in improving healthcare quality and access while managing costs, especially for underserved women and men.


Evelyn Lockhart, MD

Medical Director of University of New Mexico Transfusion Service, as well as an Associate Professor of Pathology at University of New Mexico School of Medicine. Current focal areas of her work include diagnosis of congenital platelet disorders using electron microscopy and transfusion management of obstetric hemorrhage.

Kenneth Mann, PhD

Dr. Kenneth Mann, Emeritus Professor of Biochemistry and of Medicine at the University of Vermont, has a long distinguished career characterized by quality science, well-managed large-scale interdisciplinary research enterprises and excellence in service to medical, lay and professional organizations. Among the many awards Dr. Mann has received is the latest Hemostasis and Thrombosis Research Society - HTRS - Lifetime Achievement Award.

Michael Recht, MD, PhD

Medical Director of the Oregon Hemophilia Treatment Center, and the regional director for the federally funded Hemophilia Treatment Centers in the states of Oregon, Washington, Idaho, and Alaska. Dr. Recht is a member of the Division of Pediatric Hematology/Oncology at Oregon Health and Science University and directs the pediatric hematology consult service. Current focal areas of his work include the treatment of children and adolescents affected by non-malignant blood conditions, particularly bleeding and clotting issues.

Russell E. Ware, MD, PhD

Director, Division of Hematology at Cincinnati Children's. Dr. Ware is also the Institute Co-Director of the Cancer and Blood Diseases Institute and the Associate Director of the Global Health Center. Dr. Ware has been involved with a wide variety of clinical and translational hematology research projects for 25 years, however, his primary interests have focused on sickle cell disease. He currently runs an NIH-funded laboratory effort investigating genetic modifiers of sickle cell disease.